Sanofi has agreed to acquire US-based Blueprint Medicines for an equity value of $9.1bn to bolster its immunology pipeline with rare disease treatments.
The acquisition includes Ayvakit/Ayvakyt (avapritinib), a rare immunology disease medicine approved in the US and European Union (EU), and an early-stage immunology pipeline.
Ayvakit/Ayvakyt is the only medicine for treating advanced and indolent systemic mastocytosis (ASM & ISM), a condition marked by abnormal mast cell accumulation.
The acquisition also adds elenestinib, a medicine for systemic mastocytosis, and an oral wild-type KIT inhibitor BLU-808, for a wide range of immunological diseases.
Sanofi has committed to pay $129.00 per share in cash at close.
Blueprint shareholders will obtain a non-tradeable contingent value right (CVR), which could lead to further payments based on future milestones for BLU-808. The total value, inclusive of potential CVR payments, could reach $9.5bn.
The offer price indicates a 27% premium on Blueprint's closing price as of 30 May 2025, and a 34% premium over the 30-day volume-weighted average price (VWAP).
Upon completion of the tender offer, a Sanofi subsidiary will merge with and into Blueprint, and non-tendered shares will be converted into the right to receive the same $129.00 per share in cash plus one CVR.
Sanofi plans to finance this transaction using existing cash reserves and proceeds from new debt, with no financing condition attached to the tender offer.
Sanofi CEO Paul Hudson stated: "The proposed acquisition of Blueprint Medicines represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company.
“This acquisition is fully aligned with our strategic intent to strengthen our existing therapeutic areas, to bring relevant and differentiated medicines to patients and to secure attractive returns to our shareholders.
“It complements recent acquisitions of early-stage medicines that remain our main field of interest. Sanofi still retains a sizeable capacity for further acquisitions.”
Sanofi recently agreed to acquire Vigil Neuroscience for $470m, almost a year after investing an initial $40m in the company.
